TY - JOUR
T1 - Differential modulation of PI3-kinase/Akt pathway during all-trans retinoic acid- and Am80-induced HL-60 cell differentiation revealed by DNA microarray analysis
AU - Ishida, Seiichi
AU - Shigemoto-Mogami, Yukari
AU - Shinozaki, Youichi
AU - Kagechika, Hiroyuki
AU - Shudo, Koichi
AU - Ozawa, Shogo
AU - Sawada, Jun Ichi
AU - Ohno, Yasuo
AU - Inoue, Kazuhide
N1 - Funding Information:
We thank Chie Knudsen for kind help with preparation of the supplemental table. This work was supported by Program for Promotion of Fundamental Studies in Health Sciences (MF-16 and MPJ-6) of the Organization for Pharmaceutical Safety and Research of Japan.
PY - 2004/12/1
Y1 - 2004/12/1
N2 - All-trans retinoic acid (ATRA) and Am80 are natural and synthetic derivatives of Vitamin A and have been used in the fields of oncology and dermatology for years. Their action was considered to be achieved mainly through binding to nuclear hormone receptors, retinoic acid receptors (RARs), although they have been observed to have different biological effects. For example, the two compounds have similar effects on differentiation but different effects on proliferation in human promyelocytic leukemia cell line HL-60 cells. To elucidate the genes responsible for this and other differences, we attempted for the first time to determine the genes whose expressions were differentially modulated during the time course of HL-60 cell differentiation by ATRA and Am80 treatment up to 72 h utilizing DNA microarray and clustering analyses. As a result, the expressions of 204 genes were found to be modulated differentially by ATRA and Am80. Among them, we focused on two components of the PI3-kinase/Akt signal transduction pathway, phosphoinositide-3-kinase, β-catalytic subunit and ribosomal protein S6 kinase polypeptide 1, which are related to the regulation of cell proliferation and apoptosis. Their expressions were specifically suppressed by ATRA, which coincided with the suppressive effects of ATRA on the HL-60 cell proliferation. Moreover, PI3-kinase inhibitors suppressed the proliferation of Am80-treated cells to the same extent as ATRA did. These results indicated that these gene products play a role in HL-60 cell growth suppression during the late stage of differentiation. The complete data and a list of the genes are available at http://www.nihs.go.jp/mpj/index-e.htm.
AB - All-trans retinoic acid (ATRA) and Am80 are natural and synthetic derivatives of Vitamin A and have been used in the fields of oncology and dermatology for years. Their action was considered to be achieved mainly through binding to nuclear hormone receptors, retinoic acid receptors (RARs), although they have been observed to have different biological effects. For example, the two compounds have similar effects on differentiation but different effects on proliferation in human promyelocytic leukemia cell line HL-60 cells. To elucidate the genes responsible for this and other differences, we attempted for the first time to determine the genes whose expressions were differentially modulated during the time course of HL-60 cell differentiation by ATRA and Am80 treatment up to 72 h utilizing DNA microarray and clustering analyses. As a result, the expressions of 204 genes were found to be modulated differentially by ATRA and Am80. Among them, we focused on two components of the PI3-kinase/Akt signal transduction pathway, phosphoinositide-3-kinase, β-catalytic subunit and ribosomal protein S6 kinase polypeptide 1, which are related to the regulation of cell proliferation and apoptosis. Their expressions were specifically suppressed by ATRA, which coincided with the suppressive effects of ATRA on the HL-60 cell proliferation. Moreover, PI3-kinase inhibitors suppressed the proliferation of Am80-treated cells to the same extent as ATRA did. These results indicated that these gene products play a role in HL-60 cell growth suppression during the late stage of differentiation. The complete data and a list of the genes are available at http://www.nihs.go.jp/mpj/index-e.htm.
UR - http://www.scopus.com/inward/record.url?scp=7444234742&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=7444234742&partnerID=8YFLogxK
U2 - 10.1016/j.bcp.2004.08.017
DO - 10.1016/j.bcp.2004.08.017
M3 - Article
C2 - 15498508
AN - SCOPUS:7444234742
SN - 0006-2952
VL - 68
SP - 2177
EP - 2186
JO - Biochemical Pharmacology
JF - Biochemical Pharmacology
IS - 11
ER -